Systemic lupus erythematosus: new horizons for diagnosis and therapy

Соловьев, С. К.; Асеева, Е. А.; Попкова, Т. В.; Лила, А. М.; Мазуров, В. И.; Насонов, Е. Л.

doi:10.14412/1995-4484-2020-5-14

Cited by 21 publications

(5 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…СКВ -системное аутоиммунное ревматическое заболевание неизвестной этиологии, характеризующееся гиперпродукцией органонеспецифических аутоантител к различным компонентам клеточного ядра с развитием иммуновоспалительного повреждения внутренних органов [56,57]. Поражение глаз как проявление основного заболевания выявляется у 25-50% пациентов с СКВ [58].…”

Section: системная красная волчанкаunclassified

Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease

Лисицына¹,

Alekberova²,

Давыдова

et al. 2020

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Non-infectious uveitis is the leading and insufficiently studied cause of irreversible decline in visual functions in patients with immune-mediated inflammatory rheumatic disease (IMIRDs). A multidisciplinary approach to the diagnosis and treatment of uveitis in patients with IMIRDs, involving close collaboration of rheumatologists and ophthalmologists, is the key factor for achieving favorable clinical outcomes. This article sheds light on current clinical, differential diagnostic and therapeutic challenges related to non-infectious uveitis in IMIDs-patients, with specific emphasis on state-of-the art approaches to therapy.

show abstract

Section: системная красная волчанкаunclassified

Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease

Лисицына¹,

Alekberova²,

Давыдова

et al. 2020

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

show abstract

“…Вторым значимым фактором для инициации экспертного обсуждения на республиканском уровне послужила публикация результатов большого транснационального исследования канаглифлозина -CANVAS и CANVAS-R [6].…”

Section: эндокринологияunclassified

“…ЖҚА бар науқастарды COVID 19 пандемия жағдайында емдеу ерекшеліктері Ревматологтың бақылауында болатын ЖҚЖ науқастарының көпшілігі жоспарлы түрде тағайындалатын глюкокортикоидтар (ГК), иммуносупрессанттар (ИС), гидроксихлорокин (ГХК) және гендік-инженерлік биологиялық препараттар: (ГИБП) Ритуксимаб (РТМ) және Белимумаб (БЛМ) бірнеше мақсатта тағайындалады: белсенділікті басу (дебют немесе өршу), ЖҚЖ төмен белсенділікке және ремиссияға қол жеткізу [1,6].…”

unclassified

Practical guidelines for the therapy and monitoring of patients with systemic lupus erythematosus during a pandemic COVID-19

Issayeva

Soloviev²,

Асеева³

et al. 2020

Medicine

View full text Add to dashboard Cite

Clinical manifestations of COVID-19 coronavirus infection have similar clinical symptoms to systemic lupus erythematosus (SLE). This article provides a comparative diagnosis of these two diseases. Practical recommendations are also given to doctors for the management of patients with SLE varying degrees of activity in a pandemic coronavirus infection. Key words: systemic lupus erythematosus, COVID-19, treatment.

show abstract

“…В контексте перспектив применения анти-В-клеточных препаратов особое внимание привлекает системная красная волчанка (СКВ) -классическое аутоиммунное заболевание, развитие которого связывают с нарушением В-клеточной толерантности, ведущей к гиперпродукции органоспецифических аутоантител к компонентам клеточного ядра и иммуновоспалительным повреждением внутренних органов [6]. Разнообразие иммунопатологических механизмов, лежащих в основе патогенеза СКВ [7,8], находящее свое отражение в развитии широкого спектра клинических проявлений и вариантов течения, создает существенные проблемы в разработке эффективных методов персонифицированной фармакотерапии этого заболевания [9][10][11][12][13][14]. Важным шагом в направлении решения этой проблемы явилась разработка препарата белимумаб (БЛМ), представляющего собой человеческие мАТ (IgG1λ) к BAFF (B cell-activating factor belonging to the TNF family).…”

unclassified

Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice

Насонов

Попкова²,

Лила

2021

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

Currently, strong evidence has been obtained for the fundamental role of pathological activation of B cells in the pathogenesis of immunoinflammatory (autoimmune) rheumatic diseases (IMRD), and drugs that specifically modulate the function or cause depletion of various subpopulations of B cells and plasma cells are considered a promising direction. pharmacotherapy of these diseases. of particular interest is belimumab (BLM), a human monoclonal antibody (mAb) (IgG1λ) to BAFF (B cell-activating factor belonging to the TNF family), which is the first “targeted” biological drug specially developed for the treatment of systemic lupus erythematosus (SLE). The efficacy and safety of BLM in SLE in adults and children, including lupus nephritis, in combination therapy with rituximab, steroid-sparing effect, the ability to prevent irreversible damage to internal organs dictate the need for its wider application in clinical practice.

show abstract

Systemic lupus erythematosus: new horizons for diagnosis and therapy

Cited by 21 publications

References 118 publications

Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease

Current approaches to treatment of uveitis in immune-mediated inflammatory rheumatic disease

Practical guidelines for the therapy and monitoring of patients with systemic lupus erythematosus during a pandemic COVID-19

Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice

Contact Info

Product

Resources

About